Log in

NYSE:AVNSAvanos Medical Stock Price, Forecast & News

$23.76
-0.86 (-3.49 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$22.85
Now: $23.76
$25.60
50-Day Range
$20.64
MA: $28.53
$34.41
52-Week Range
$19.46
Now: $23.76
$48.07
Volume352,578 shs
Average Volume425,642 shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. The company also offers Game Read, a product for pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries; GRPro 2.1, a cold and compression therapy system; Med4Elite, a multi-modality therapy unit; ATX Wraps; and various product accessories. In addition, it sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and GAME READY brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Read More
Avanos Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.9Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone844-428-2667

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$697.60 million
Cash Flow$1.85 per share
Book Value$26.40 per share

Profitability

Net Income$-45,900,000.00

Miscellaneous

Employees4,700
Market Cap$1.13 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive AVNS News and Ratings via Email

Sign-up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter.


Avanos Medical (NYSE:AVNS) Frequently Asked Questions

How has Avanos Medical's stock been impacted by COVID-19 (Coronavirus)?

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVNS shares have decreased by 18.1% and is now trading at $23.76. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avanos Medical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Avanos Medical.

When is Avanos Medical's next earnings date?

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Avanos Medical.

How were Avanos Medical's earnings last quarter?

Avanos Medical Inc (NYSE:AVNS) announced its quarterly earnings results on Tuesday, February, 25th. The company reported $0.34 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.32 by $0.02. The firm had revenue of $189.80 million for the quarter, compared to the consensus estimate of $178.58 million. Avanos Medical had a negative net margin of 6.58% and a positive return on equity of 3.99%. The business's revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.30 EPS. View Avanos Medical's earnings history.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical updated its FY20 earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of $1.00-1.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.16. The company issued revenue guidance of +5-7% yr/yr to $732.5-746.4 million, compared to the consensus revenue estimate of $736.83 million.

What price target have analysts set for AVNS?

6 brokers have issued 12 month target prices for Avanos Medical's stock. Their forecasts range from $29.00 to $48.00. On average, they anticipate Avanos Medical's share price to reach $34.20 in the next year. This suggests a possible upside of 43.9% from the stock's current price. View analysts' price targets for Avanos Medical.

Has Avanos Medical been receiving favorable news coverage?

Media headlines about AVNS stock have been trending very negative on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Avanos Medical earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAvanos Medical.

Are investors shorting Avanos Medical?

Avanos Medical saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 3,230,000 shares, an increase of 11.0% from the February 13th total of 2,910,000 shares. Based on an average trading volume of 374,300 shares, the short-interest ratio is presently 8.6 days. Currently, 6.8% of the company's stock are sold short. View Avanos Medical's Current Options Chain.

Who are some of Avanos Medical's key competitors?

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly Clark (KMB), AT&T (T), Honeywell International (HON), Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Altria Group (MO), Procter & Gamble (PG), Verizon Communications (VZ) and Cisco Systems (CSCO).

Who are Avanos Medical's key executives?

Avanos Medical's management team includes the following people:
  • Mr. Joseph F. Woody, CEO & Director (Age 53)
  • Mr. John W. Wesley, Sr. VP of Legal & Gov. Relations (Age 60)
  • Mr. John R. Tushar, Pres of Global Franchises (Age 57)
  • Mr. Arjun Ranjan Sarker, Sr. VP of International (Age 53)
  • Mr. Warren J. MacHan, Sr. VP of Bus. Strategy & Interim CFO (Age 53)

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

How do I buy shares of Avanos Medical?

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $23.76.

How big of a company is Avanos Medical?

Avanos Medical has a market capitalization of $1.13 billion and generates $697.60 million in revenue each year. The company earns $-45,900,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. Avanos Medical employs 4,700 workers across the globe. View additional information about Avanos Medical.

What is Avanos Medical's official website?

The official website for Avanos Medical is http://avanos.com/.

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 WINDWARD PARKWAY, ALPHARETTA GA, 30004. The company can be reached via phone at 844-428-2667 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel